Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock
Rhea-AI Summary
Humacyte (Nasdaq: HUMA) entered a registered direct offering to sell 25,000,000 shares, expected to raise gross proceeds of $20.0 million, with closing on or about March 20, 2026.
Proceeds are intended to fund commercialization of Symvess for vascular trauma, a BLA supplement filing and the upcoming Phase 3 hemodialysis read-out, pipeline development, and general corporate purposes.
Positive
- Gross proceeds of $20.0 million expected
- Offering proceeds targeted to commercialize Symvess in vascular trauma
- Funds allocated for planned BLA supplement and Phase 3 read-out
Negative
- Company is selling all 25,000,000 shares, creating dilution risk for existing holders
- Timing: closing subject to customary conditions on or about March 20, 2026
News Market Reaction – HUMA
In the Mar 19 session, HUMA declined 19.42%, reflecting a significant negative market reaction. Argus tracked a trough of -29.9% from its starting point during tracking. Our momentum scanner triggered 29 alerts that day, indicating elevated trading interest and price volatility. Trading volume was elevated at 2.1x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Oct 07 | Registered direct offering | Negative | -33.7% | Oversubscribed $60M direct offering with matching-share warrants under shelf. |
| Mar 25 | Public stock offering | Negative | -30.4% | Pricing of $50M public offering of 25M shares at $2.00 per share. |
| Mar 25 | Proposed stock offering | Negative | -30.4% | Announcement of underwritten common stock offering with 15% overallotment. |
| Nov 14 | Registered direct deal | Negative | -9.4% | $15M direct offering of stock plus equal-number warrants at $5.34. |
| Oct 04 | Registered direct deal | Negative | +3.0% | $30M direct offering of stock and warrants at $5.28, mixed warrant terms. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Past Humacyte equity offerings have typically been followed by share price declines, with most same-tag events showing double-digit negative reactions.
Over the past year, Humacyte has repeatedly used equity offerings to raise capital, including $30.0M, $15.0M, and an oversubscribed $60.0M registered direct deal, plus a $50M public offering at $2.00 per share. These financings often included warrants and were conducted under an effective registration. Share reactions to these offerings were mostly negative, with four of five tagged events showing steep declines, framing today’s $20M direct offering within an established dilution pattern.
Key Terms
registered direct offering financial
securities purchase agreement financial
phase 3 medical
biologics license application regulatory
prospectus supplement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Net proceeds from the offering will fund the commercialization of Symvess® in the vascular trauma indication and provide funding beyond key milestones such as the upcoming read-out of Phase 3 results in hemodialysis
The offering was led by a new life science dedicated investor and a long-only mutual fund
DURHAM, N.C., March 19, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has entered into a securities purchase agreement with several new institutional investors for the purchase and sale of 25,000,000 shares of common stock pursuant to a registered direct offering. The offering was led by a new life science dedicated investor and a long-only mutual fund. The gross proceeds from this offering are expected to be
Titan Partners, a division of American Capital Partners, is acting as sole placement agent for the offering.
Humacyte intends to use the net proceeds that it will receive from the offering to fund the commercialization of Symvess in the vascular trauma indication, the planned filing of a Biologics License Application supplement in a hemodialysis indication and related activities including the upcoming read-out of Phase 3 results, the development of the product candidates in Humacyte’s pipeline and for working capital and general corporate purposes.
A shelf registration statement on Form S-3 (No. 333-290231) was previously filed with the Securities and Exchange Commission (the “SEC”) on September 12, 2025 and declared effective by the SEC on September 22, 2025. The securities are being offered by means of a prospectus supplement and accompanying prospectus relating to the offering that form a part of the registration statement. The prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Before investing in the offering, you should read each of the prospectus supplement and the accompanying prospectus relating to the offering in their entirety as well as the other documents that Humacyte has filed with the SEC that are incorporated by reference in the prospectus supplement and the accompanying prospectus relating to the offering, which provide more information about Humacyte and the offering. Copies of the prospectus supplement, when available, and accompanying prospectus relating to the offering may be obtained from Titan Partners Group LLC, a division of American Capital Partners, LLC, 4 World Trade Center, 49th Floor, New York, NY 10007, by phone at (929) 833-1246 or by email at prospectus@titanpartnersgrp.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, and in the first quarter of 2025 commenced the United States commercial launch of Symvess, its first FDA-approved product. Humacyte is pioneering the development and manufacture of off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. Humacyte believes its regenerative medicine technology has the potential to overcome limitations in existing standards of care and address the lack of significant innovation in products that support tissue repair, reconstruction and replacement. Humacyte is leveraging its novel, scalable technology platform to develop proprietary, bioengineered, acellular human tissues for use in the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.
For uses other than the U.S. Food and Drug Administration (“FDA”) approval in the extremity vascular trauma indication, the acellular tissue engineered vessel (“ATEV”) is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.
Forward-Looking Statements
This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although Humacyte believes that it has a reasonable basis for each forward-looking statement contained in this press release, Humacyte cautions you that these statements are based on a combination of facts and factors currently known by it and its projections of the future, about which Humacyte cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements regarding the timing and satisfaction of customary closing conditions of the offering; the anticipated use of proceeds from the offering; Humacyte’s plans and ability to commercialize Symvess and, if approved by regulatory authorities, its product candidates, successfully and on Humacyte’s anticipated timelines; Humacyte’s ability to manufacture Symvess and, if approved by regulatory authorities, its product candidates in sufficient quantities to satisfy its clinical trial and commercial needs; the anticipated benefits of the ATEVs relative to existing alternatives; Humacyte’s ability to design, initiate and successfully complete clinical trials and other studies for its product candidates and its plans and expectations regarding ongoing or planned clinical trials; Humacyte’s plans and ability to execute product development, process development and preclinical development efforts successfully and on its anticipated timelines; and Humacyte’s plans, anticipated timeline and ability to file applications for, and obtain marketing approvals from the FDA and other regulatory authorities for the ATEVs and product candidates. Humacyte cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, and/or competitive factors, and other risks and uncertainties, including those described under the header “Risk Factors” in Humacyte’s Annual Report on Form 10-K for the year ended December 31, 2024 and in Humacyte’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, each filed by Humacyte with the SEC, and in future SEC filings. Most of these factors are outside of Humacyte’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by Humacyte or any other person that Humacyte will achieve its objectives and plans in any specified time frame, or at all. Except as required by law, Humacyte has no current intention of updating any of the forward-looking statements in this press release. You should, therefore, not rely on these forward-looking statements as representing Humacyte’s views as of any date subsequent to the date of this press release.
Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com
Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com
